Clinical Trial Conduct Investigations Are “Coming Storm” For Rx Industry, U.S. Attorney Sheehan Says
This article was originally published in The Pink Sheet Daily
Investigations into institutional review board practices will likely focus on compliance with subject disclosure and protection issues, Sheehan tells the International Pharmaceutical Compliance Summit in Philadelphia.
You may also be interested in...
Investigation into Lilly's marketing and promotional practices is focused on Evista, Prozac and Zyprexa, company says. Subpoenas may reflect Philadelphia prosecutor's interest in PBMs and Federal Employee Health Benefits Program.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.